Keyphrases
Cystic Fibrosis
100%
Polyelectrolyte
100%
Surface Active
100%
Lung Infection
100%
Nanomedicine
100%
Mucus
57%
Colistin
42%
Nanoparticles
42%
Lung
42%
Nebulizer
42%
Inhalation
42%
Tobramycin
28%
Bacterial Biofilm
28%
Pseudomonas Aeruginosa (P. aeruginosa)
28%
Controlled Release
28%
Aminoglycosides
28%
Biofilm
28%
Aerosolized
28%
Cargo
14%
Lung Microenvironment
14%
Lung Disease
14%
Biofilm Infection
14%
Polyelectrolyte Complex Nanoparticles
14%
Specific Delivery
14%
Drug Delivery Technology
14%
Biomolecular
14%
Nephrotoxicity
14%
Standard of Care
14%
Systemic Administration
14%
Self-assembly
14%
Systemic Exposure
14%
Antibiotic Dosage
14%
Gram-positive
14%
Improved Activity
14%
Multidrug-resistant Organisms
14%
Antibiotic Therapy
14%
Cystic Fibrosis Transmembrane Conductance Regulator
14%
Adverse Effects
14%
Antimicrobial Activity
14%
Life Expectancy
14%
Staphylococcus Aureus
14%
Drug Distribution
14%
Biofilm Eradication
14%
Physiological Barriers
14%
Chronic Infection
14%
Cystic Fibrosis Sputum
14%
Cystic Fibrosis Foundation
14%
Gram-negative
14%
Approved Drugs
14%
Genetic Disease
14%
Dry Powder Inhaler
14%
U.S. Administration
14%
Cationic Antimicrobial Peptides
14%
P. Aeruginosa Infection
14%
Game Changer
14%
Release Behavior
14%
Pharmacology, Toxicology and Pharmaceutical Science
Cystic Fibrosis
100%
Polyelectrolyte
100%
Nanomedicine
100%
Lung Infection
100%
Nanoparticle
44%
Pseudomonas aeruginosa
33%
Nebulizer
33%
Colistimethate
33%
Infection
22%
Tobramycin
22%
Aminoglycoside
22%
Controlled Release
22%
Life Expectancy
11%
Antibiotic Therapy
11%
Side Effect
11%
Systemic Administration
11%
Bacterial Infection
11%
Drug Distribution
11%
Staphylococcus Aureus
11%
Cystic Fibrosis Transmembrane Conductance Regulator
11%
Lung Disease
11%
Nephrotoxicity
11%
Dry Powder Inhaler
11%
Antimicrobial Cationic Peptide
11%
Genetic Disorder
11%
Antimicrobial Agent
11%